We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CCR5 Antagonism Impacts Vaccination Response and Immune Profile in HIV-1 Infection.
- Authors
Westrop, Samantha J.; Moyle, Graeme; Jackson, Akil; Nelson, Mark; Mandalia, Sundhiya; Imami, Nesrina
- Abstract
Maraviroc (MVC) is the first licensed antiretroviral therapeutic agent to target a host cell surface molecule, and successful HIV-1 entry blockade by this C-C chemokine receptor type 5 (CCR5)-antagonist potentiates immunomodulation. We hypothesized that MVC intensification impacts immunization responses, T-cell phenotype, function and delayed type hypersensitivity (DTH) in HIV-1+ subjects. A 24-wk, double-blinded, placebo-controlled study of the addition of MVC to suppressive antiretroviral therapy in HIV-1+ persons was performed. Subjects received DTH tests, intramuscular tetanus, meningococcal and oral cholera immunizations. Anti-body titers, T-cell function and phenotype were assessed. Of 157 patients referred, 47 were randomized 1:1; MVC:placebo. MVC enhanced meningococcal neo-immunization, blunted cholera response and expedited lymphoproliferation to tetanus boost, without affecting recall humoral response. Anti-HIV-1 group-specific antigen (Gag) and tetanus toxoid (TTox) function improved significantly, HIV-1-associated CD8 T-cell skewing normalized, and the percentage of late-stage and major histocompatibility complex (MHC) class II expressing CD4 T-cells increased. Activated CD4+ CD38+ human leukocyte antigen (HLA)-DR+ T-cells declined, and costimulation shifted to coinhibition. DTH was unchanged. Maraviroc intensification, through antagonism of the cell surface molecule CCR5, favorably influences immune profiles of HIV-1+ patients, supporting its immunomodulatory use in HIV-1 infection and potentially in other immunologically relevant settings.
- Subjects
HIV-positive persons; VACCINATION; PATIENTS; IMMUNIZATION; T cells
- Publication
Molecular Medicine, 2012, Vol 18, Issue 10, p1240
- ISSN
1076-1551
- Publication type
Article
- DOI
10.2119/molmed.2012.00206